Ocugen (OCGN) News Today $1.02 -0.03 (-2.86%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.03 +0.01 (+0.59%) As of 08/29/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCGN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Ocugen (NASDAQ:OCGN) Stock Price Up 3% - Here's WhyAugust 27 at 2:42 AM | marketbeat.comOcugen IncAugust 25, 2025 | edition.cnn.comOcugen reports EMA positive advice for acceptability of OCU410STAugust 13, 2025 | msn.comOcugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt DiseaseAugust 13, 2025 | globenewswire.comOcugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and WarrantsAugust 12, 2025 | globenewswire.comOcugen, Inc. Announces $20 Million Securities Purchase Agreement with Janus Henderson InvestorsAugust 8, 2025 | quiverquant.comQOcugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and WarrantsAugust 8, 2025 | globenewswire.comFY2025 EPS Estimates for Ocugen Increased by Chardan CapitalAugust 8, 2025 | marketbeat.comHC Wainwright Has Positive Outlook of Ocugen FY2025 EarningsAugust 8, 2025 | marketbeat.comOcugen's (OCGN) "Buy" Rating Reiterated at Chardan CapitalAugust 5, 2025 | marketbeat.com3OCGN : Demystifying Ocugen: Insights From 5 Analyst ReviewsAugust 4, 2025 | benzinga.comOcugen (NASDAQ:OCGN) Posts Earnings Results, Beats Expectations By $0.01 EPSAugust 4, 2025 | marketbeat.comOcugen, Inc. (NASDAQ:OCGN) Q2 2025 Earnings Call TranscriptAugust 2, 2025 | msn.comOcugen Inc’s Earnings Call: Progress Amid Financial ChallengesAugust 2, 2025 | msn.comOcugen Reports Progress in Gene Therapy TrialsAugust 1, 2025 | tipranks.comOcugen Wins Dismissal of Securities LawsuitAugust 1, 2025 | theglobeandmail.comOcugen (OCGN) Q2 Revenue Jumps 20%August 1, 2025 | fool.comOcugen, Inc. (OCGN) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | seekingalpha.comOcugen Provides Business Update with Second Quarter 2025 Financial ResultsAugust 1, 2025 | globenewswire.comOcugen Q2 2025 Earnings PreviewAugust 1, 2025 | msn.comGSA Capital Partners LLP Increases Stake in Ocugen, Inc. (NASDAQ:OCGN)July 31, 2025 | marketbeat.comOcugen (OCGN) to Release Quarterly Earnings on FridayJuly 25, 2025 | marketbeat.comOcugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three YearsJuly 23, 2025 | msn.comOcugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership TeamJuly 21, 2025 | globenewswire.comOcugen Doses First Patient in Pivotal Trial for Stargardt Gene TherapyJuly 20, 2025 | msn.comOcugen Announces Q2 2025 Financial Results Call and Business UpdateJuly 18, 2025 | msn.comOcugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for ...July 18, 2025 | gurufocus.comOcugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for ...July 18, 2025 | gurufocus.comOcugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt DiseaseJuly 18, 2025 | globenewswire.comOcugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial ResultsJuly 17, 2025 | globenewswire.comOcugen (NASDAQ:OCGN) Shares Down 2.8% - Should You Sell?July 17, 2025 | marketbeat.comOcugen's (OCGN) "Buy" Rating Reaffirmed at HC WainwrightJune 24, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Given "Buy" Rating at Chardan CapitalJune 24, 2025 | marketbeat.comCarisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic DiseasesJune 23, 2025 | globenewswire.comOcugen: Three Potential Gene-Therapy Filings By 2028June 18, 2025 | seekingalpha.comOcugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt DiseaseJune 17, 2025 | msn.comOcugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate ...June 16, 2025 | gurufocus.comOcugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt DiseaseJune 16, 2025 | globenewswire.comBank of America Corp DE Sells 583,634 Shares of Ocugen, Inc. (NASDAQ:OCGN)June 14, 2025 | marketbeat.comOcugen To Present at BIO International Convention 2025June 11, 2025 | globenewswire.comOcugen Secures Licensing Agreement for OCU400 in KoreaJune 6, 2025 | msn.comOcugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in KoreaJune 5, 2025 | globenewswire.comJane Street Group LLC Purchases 357,891 Shares of Ocugen, Inc. (NASDAQ:OCGN)June 1, 2025 | marketbeat.comOcugen wins FDA rare pediatric disease status for genetic eye disorder treatmentMay 27, 2025 | msn.comOcugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt DiseaseMay 27, 2025 | globenewswire.comNoble Financial Predicts Ocugen's Q2 Earnings (NASDAQ:OCGN)May 16, 2025 | marketbeat.comThe Analyst Verdict: Ocugen In The Eyes Of 5 ExpertsMay 14, 2025 | nasdaq.comOcugen (NASDAQ:OCGN) Price Target Cut to $7.00 by Analysts at HC WainwrightMay 14, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Releases Earnings Results, Beats Estimates By $0.01 EPSMay 13, 2025 | marketbeat.comOcugen Reports Progress in Q1 2025 with Advancements in Gene TherapyMay 13, 2025 | msn.com Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCGN Media Mentions By Week OCGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCGN News Sentiment▼0.721.05▲Average Medical News Sentiment OCGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCGN Articles This Week▼33▲OCGN Articles Average Week Get the Latest News and Ratings for OCGN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Ocugen and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Moderna News Pfizer News CureVac News Calliditas Therapeutics AB (publ) News Precigen News Enliven Therapeutics News LENZ Therapeutics News Zymeworks News Arcus Biosciences News Structure Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCGN) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
